Posts by: Marisa Wexler, MS

Marisa Wexler, MS

Marisa holds an MS in Cellular and Molecular Pathology from the University of Pittsburgh, where she studied novel genetic drivers of ovarian cancer. She specializes in cancer biology, immunology, and genetics. Marisa began working with BioNews in 2018, and has written about science and health for SelfHacked and the Genetics Society of America. She also writes/composes musicals and coaches the University of Pittsburgh fencing club.

September 9, 2020September 9, 2020

Small Hereditary Angioedema Study Supports Efficacy of Ionis’ ASOs

News

Antisense oligonucleotides (ASOs) being developed by Ionis Pharmaceuticals may reduce the frequency of attacks in people with hereditary angioedema (HAE), a small study suggests. The study, “Antisense Inhibition of Prekallikrein ... Read more

August 19, 2020August 19, 2020

Orladeyo Set to Launch by Year’s End if Approved, BioCryst Says

News

BioCryst Pharmaceuticals is prepared to launch Orladeyo (berotralstat), an oral treatment for hereditary angioedema (HAE), by the end of the year if the medication is approved, the company has ... Read more

July 22, 2020October 15, 2020

KalVista Anticipates Milestones in 2 HAE Treatment Candidates in Second Half of 2020

News

KalVista Pharmaceuticals anticipates beginning a Phase 2 clinical trial in the second half of this year to test KVD824, an investigational preventive treatment for hereditary angioedema (HAE). In addition, ... Read more

July 15, 2020July 15, 2020

Cipla Given FDA Approval for Icatibant, Generic Version of Firazyr

News

Cipla has received final approval from the U.S. Food and Drug Administration (FDA) for a generic version of Firazyr (icatibant injection), an approved treatment for acute attacks in adults with hereditary ... Read more

June 19, 2020June 19, 2020

Ruconest More Cost-effective Than Other On-demand Treatments for HAE Attacks, Study Estimates

News

Ruconest, a recombinant human form of the C1 inhibitor protein, is more cost-effective than other on-demand therapies at treating attacks in people with hereditary angioedema, a new study suggests. ... Read more

June 12, 2020June 12, 2020

Data Support Long-term Efficacy of Berotralstat in HAE, BioCryst Says

News

New clinical trial data show that BioCryst Pharmaceuticals‘ investigational therapy for hereditary angioedema (HAE), berotralstat, reduces the frequency of HAE attacks and improves patients’ quality of life through 48 ... Read more

May 6, 2020May 6, 2020

European Commission Approves Ruconest for Acute Swelling in Children with HAE

News

The European Commission has approved Pharming‘s Ruconest (conestat alfa) for the treatment of acute swelling episodes in young children with hereditary angioedema (HAE). This approval expands the age range for ... Read more

March 5, 2020March 23, 2020

Mutations May Raise Risk of Angioedema Linked to Blood Pressure Medicines

News

Mutations in the KCNMA1 gene may predispose certain people to angioedema caused by blood pressure medications, a study suggests. The study, “Genome-wide association study of angioedema induced by angiotensin-converting enzyme ... Read more

March 3, 2020March 5, 2020

Test Using Dried Blood Spot May Be Simple Way to Diagnose HAE

News

A new diagnostic test for hereditary angioedema (HAE) can measure the activity of C1-inhibitor (C1-INH) in a drop of dried blood, and may be easy enough to use at ... Read more

February 18, 2020February 26, 2020

Study Identifies Novel Molecular Players as Potential Therapeutic Target in Bradykinin-mediated Swelling Attacks

News

Bradykinin, a key molecular player involved in swelling attacks in hereditary angioedema patients, does so by signaling through the cyclooxygenase (COX) proteins, which may be targeted with common anti-inflammatory ... Read more

Pin It on Pinterest